Managing Comorbidities and Treatment Planning in Metastatic Castration Sensitive Prostate Cancer (mCSPC)

In this segment, Dr. Charles J. Ryan invites Dr. Murilo De Almeida Luz to discuss how the growing burden of comorbidities and polypharmacy affects treatment planning for patients with metastatic castration sensitive prostate cancer (mCSPC). Dr. Luz explains that many patients present with significant cardiovascular disease, diabetes, metabolic syndrome, and other chronic conditions that require careful consideration when selecting systemic therapy. He emphasizes that clinicians must evaluate the patient’s overall health status, baseline functional capacity, and current medications to minimize potential drug–drug interactions and treatment related toxicities. The discussion highlights how treatment selection increasingly involves balancing the benefits of therapy intensification with the need to maintain long term tolerability and patient safety. Dr. Luz also notes the importance of coordination with other specialists and primary care providers to optimize management of comorbid conditions. Overall, the segment underscores how the complexity of modern mCSPC patients shapes individualized treatment strategies in routine clinical practice.